Dosage and Treatment of Advanced Solid Tumors
common.study.values.description
“A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors”
The purpose of this study is to investigate BMS-986226 administered alone or in combination with nivolumab or ipilimumab.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - BMS-986226
specified dose on specified days
Biological - Nivolumab
specified dose on specified days
Biological - Ipilimumab
specified dose on specified days
Biological - Tetanus Vaccine
specified dose on specified days
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
common.study.values.clinical-trial-id
NCT03251924
participant.views.study.view.id
Xe0zXb
